


**Supplementary Table 1.** Primer sequences used for RT-PCR


| Human primers  | Sequences (5' → 3')                                       | GenBank reference sequences   |
|----------------|---|-------------------------------|
| <i>β-actin</i> | F-GGACTTCGAGCAAGAGATGG<br>R-AGCACTGTGTTGGCGTACAG          | NM_001101.4 → NP_001092.1     |
| <i>AGT</i>     | F-AAAGCAGCCGTTTCTCCTTG<br>R-TTCACAAACAAGCTGGTCGG          | NM_001101.4 → NP_001092.1     |
| <i>MCP-1</i>   | F-CCCCAGTCACCTGCTGTTAT<br>R-TGGAATCCTGAACCCACTTC          | NM_002982.3 → NP_002973.1     |
| <i>Renin</i>   | F-TCGTCTTTGACACTGGTTCGTCCA<br>R-AGCCACTGACTGTCCCTGTTGAAT  | NM_000537.3 → NP_000528.1     |
| <i>TGF-β</i>   | F-GGGACTATCCACCTGCAAGA<br>R-CCTCCTTGGCGTAGTAGTCG          | NM_000660.6 → NP_000651.3     |
| <i>IL-6</i>    | F-CCAGCTATGAACTCCTTCTC<br>R-GCTTGTTCCTCACATCTCTC          | NM_000600.4 → NP_000591.1     |
| Mouse primers  | Sequences (5' → 3')                                       | GenBank reference sequences   |
| <i>Gapdh</i>   | F-TGCCTCCTGCACCACCAACT<br>r- TGCCTCCTGCACCACCAACT         | NP_001256799.2 → NP_001243728 |
| <i>Agt</i>     | F-CCTCCCGACTAGATGGACAC<br>r-AAATCCAGAGAGCGTGGGAA          | NM_007428.3 → NP_031454.3     |
| <i>Mcp-1</i>   | F- TTA AAAACCTGGATCGGAACCAA<br>r- GCATTAGCTTCAGATTTACGGGT | NM_011333.3 → NP_035463.1     |
| <i>Renin</i>   | F- CCTCTACCTTGCTTGTGGGA<br>r- ATGCCTAGAACCCCGTCAAA        | NM_031192.3 → NP_112469.1     |
| <i>Tgf-β</i>   | F-TGACGTCACTGGAGTTGTACGG<br>r- GGTTTCATGTCATGGATGGTGC     | NM_021578.2 → NP_067589.1     |

RT-PCR, real time polymerase chain reaction; AGT, angiotensinogen; MCP-1, monocyte chemotactic protein-1; TGF-β, transforming growth factor beta 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.






**Supplementary Figure 1.** Glucose homeostasis in vehicle- and drug-treated *db/db* mice. (A) Measurement of blood glucose during oral glucose tolerance test of 9 week administration after 6-hr fasting in vehicle (black square, ■), pioglitazone (white circle, ○), dapagliflozin (white square, □), combination (black circle, ●), and (B) area under the curve of the oral glucose concentration. Data are means  $\pm$  SEM (n = 5-8). \* $p$  < 0.05 vs vehicle by one-way ANOVA and **Tukey's** post hoc test.



**Supplementary Figure 2.** Effects of pioglitazone, dapagliflozin and combination on lipid concentration. (A) Measurement of serum triglyceride and (B) serum free fatty acid after 9 weeks treatment in vehicle (PBS), pioglitazone (30 mg/kg/day), dapagliflozin (1 mg/kg/day), and combination (30 mg/kg/day of pioglitazone and 1 mg/kg/day of dapagliflozin). Data are means  $\pm$  SEM (n = 5-8). \* $p$  < 0.05 vs vehicle, \*\* $p$  < 0.001 vs vehicle by one-way ANOVA and **Tukey's** post hoc test.



1 **Supplementary Figure 3.** Effect of pioglitazone, dapagliflozin, and combination therapy on  
2 inflammatory, profibrotic, and renin-angiotensin system-related gene expression and cell  
3 viability of HK-2 cells. HK-2 cell were exposed to either 5.5 mM glucose (normal glucose,  
4 NG), 50 mM glucose (high glucose, HG), 0.3 mM palmitic acid (PA), 10  $\mu$ M pioglitazone  
5 (PIO), 10  $\mu$ M dapagliflozin (DAPA), or 10  $\mu$ M pioglitazone plus 10  $\mu$ M dapagliflozin  
6 (COMBI). Real-time PCR for 24 hr cultured HK-2 cells for (A) transforming growth factor- $\beta$ ,  
7 (B) monocyte chemoattractant protein-1, (C) interleukin-6, and (D) angiotensinogen. (E)  
8 MTT assay was performed to determine cell viability in HK-2 cell. Data are means  $\pm$  SEM (n  
9  $\geq$  4). \* $p$  < 0.05 vs high glucose and palmitic acid group, \*\* $p$  < 0.001 vs high glucose and  
10 palmitic acid group by one-way ANOVA and **Tukey's** post hoc test.



15 **Supplementary Figure 4.** Effect of pioglitazone, dapagliflozin, and combination therapy on  
16 SGLT2 protein expression in human proximal tubular cells (HK-2 cells). HK-2 cell were  
17 exposed to either 5.5 mM glucose (normal glucose, NG), 50 mM glucose (high glucose, HG),  
18 0.3 mM palmitic acid (PA), 10  $\mu$ M pioglitazone (PIO), 10  $\mu$ M dapagliflozin (DAPA), or 10  
19  $\mu$ M pioglitazone plus 10  $\mu$ M dapagliflozin (COMBI). Western immunoblot for 24 hr cultured  
20 HK-2 cells for (A) total cell membrane sodium glucose co-transporter 2 (SGLT2) expression  
21 and (B) quantitative analysis of SGLT2. Data are means  $\pm$  SEM (n=4). The concentration of  
22 SGLT2 protein in the HK-2 membrane fraction was not different between the groups ( $p =$   
23 0.786).

